Bevacizumab (Avastin, Genentech) is a recombinant humanised, full length, anti-VEGF monoclonal antibody that binds all isoforms of VEGF-A. It has been shown to prolong survival of patients with advanced colon cancer when combined with 5-fluorouracil. 1 In this report, we describe the effect of bevacizumab in two patients with choroidal neovascularisation (CNV) secondary to pathological myopia, which was refractory to other treatment.
No takes yet. Share an insight, caveat, or question.
Quan Dong Nguyen (2005) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: